title: Prognostic significance of flow cytometric immunophenotyping in acute myeloid leukemia.
abstract: The prognostic significance of flow cytometric immunophenotyping (FCI) in acute myeloid leukemia (AML) has been controversial. In this study, we re-investigated the possible role of FCI in the prediction of AML relapse following standard chemotherapy. A total of 209 AML cases with follow-up information were analyzed. Among those, 78 cases were in remission (M:F=44/34; mean age of 48.9 years) and 131 had relapse (M:F=71/60; mean age of 51.3 years). The expression of CD34, HLA-DR or a combination of both was significantly different between the remission and relapse groups for all AML as well as AML without t(15;17). None of the pammyeloid markers or their combinations analyzed was found to correlate with treatment outcomes. Complex cytogenetic abnormalities were more likely associated with relapse group than with remission group, but were not statistically significant after excluding AML with t(15;17). In conclusion, FCI is useful in predicting treatment outcome and disease relapse in AML.
authors.affiliation: Department of Pathology and Laboratory Medicine, Emory University School of Medicine Atlanta, GA, USA.
authors.forename: Brian A
authors.initials: BA
authors.lastname: Webber
authors.forename: Melissa M
authors.initials: MM
authors.lastname: Cushing
authors.forename: Shiyong
authors.initials: S
authors.lastname: Li
references.citation: Leukemia. 2006 May;20(5):888-91
references.pmid: 16525493
references.citation: Blood. 1991 May 15;77(10):2242-50
references.pmid: 1709379
references.citation: Leukemia. 1992 May;6(5):393-9
references.pmid: 1375696
references.citation: Leuk Res. 1994 Jan;18(1):29-35
references.pmid: 8289464
references.citation: Am J Clin Pathol. 2002 Oct;118(4):560-6
references.pmid: 12375643
references.citation: Haematologica. 2004 May;89(5):528-40
references.pmid: 15136215
references.citation: Leuk Res. 2005 Oct;29(10):1109-16
references.pmid: 16095690
references.citation: Am J Clin Pathol. 1998 Feb;109(2):211-20
references.pmid: 9583894
references.citation: Leuk Res. 2007 Jan;31(1):113-6
references.pmid: 16730795
references.citation: Ann Hematol. 2007 May;86(5):311-27
references.pmid: 17375301
references.citation: J Cancer Res Clin Oncol. 1994;120(9):553-7
references.pmid: 8045921
references.citation: Leukemia. 1994 Mar;8(3):388-94
references.pmid: 7907393
references.citation: Leuk Lymphoma. 1995 Mar;17(1-2):111-9
references.pmid: 7539657
references.citation: Cancer Res. 2001 Jun 1;61(11):4483-9
references.pmid: 11389079
references.citation: J Clin Oncol. 1990 Mar;8(3):423-30
references.pmid: 2307987
references.citation: Am J Clin Pathol. 2000 Feb;113(2):193-200
references.pmid: 10664621
references.citation: Haematologica. 2002 Nov;87(11):1135-40
references.pmid: 12414342
references.citation: Blood. 1995 Apr 15;85(8):2147-53
references.pmid: 7536492
references.citation: Arch Pathol Lab Med. 2003 Jan;127(1):42-8
references.pmid: 12521365
references.citation: Leukemia. 1998 Jul;12(7):1056-63
references.pmid: 9665190
references.citation: Leukemia. 1992 Nov;6(11):1203-9
references.pmid: 1279324
references.citation: Hematol Oncol. 1990 Jan-Feb;8(1):47-58
references.pmid: 2404842
references.citation: Am J Hematol. 2006 Apr;81(4):227-35
references.pmid: 16550517
references.citation: Leuk Res. 2004 Jan;28(1):43-8
references.pmid: 14630079
references.citation: Br J Haematol. 1989 Jun;72(2):161-6
references.pmid: 2757962
references.citation: Blood. 1995 Oct 15;86(8):3097-108
references.pmid: 7579404
references.citation: Leukemia. 1994 May;8(5):823-6
references.pmid: 7514247
references.citation: Blood. 1998 Oct 1;92(7):2322-33
references.pmid: 9746770
references.citation: Baillieres Clin Haematol. 1996 Mar;9(1):87-105
references.pmid: 8730552
references.citation: Cancer. 2006 Feb 15;106(4):839-47
references.pmid: 16419072
references.citation: Leukemia. 1997 Nov;11(11):1878-86
references.pmid: 9369421
references.citation: Am J Clin Pathol. 1992 Oct;98(4):430-6
references.pmid: 1415023
references.citation: Leuk Res. 1997 Oct;21(10):985-95
references.pmid: 9403009
references.citation: Am J Hematol. 1998 Aug;58(4):278-84
references.pmid: 9692390
references.citation: Leukemia. 2007 Jun;21(6):1204-11
references.pmid: 17410192
references.citation: Blood. 2000 Aug 1;96(3):870-7
references.pmid: 10910899
references.citation: Neoplasma. 2005;52(5):402-10
references.pmid: 16151585
references.citation: Blood. 1994 Aug 15;84(4):1220-5
references.pmid: 8049437
references.citation: Leuk Res. 1997 Jul;21(7):603-7
references.pmid: 9301680
references.citation: Haematologica. 2001 Aug;86(8):801-6
references.pmid: 11522535
references.citation: Blood. 1998 May 1;91(9):3401-13
references.pmid: 9558399
references.citation: Haematologica. 1993 May-Jun;78(3):151-5
references.pmid: 7690733
references.citation: Neoplasma. 2006;53(2):155-60
references.pmid: 16575472
references.citation: Leukemia. 2003 Apr;17(4):707-15
references.pmid: 12682628
references.citation: Semin Hematol. 2001 Apr;38(2):124-38
references.pmid: 11309694
references.citation: Blood. 1997 Aug 15;90(4):1643-8
references.pmid: 9269784
references.citation: Am J Hematol. 2001 Oct;68(2):69-74
references.pmid: 11559944
references.citation: Blood. 1993 May 1;81(9):2399-405
references.pmid: 7683218
references.citation: Leuk Lymphoma. 1994;13 Suppl 1:81-5
references.pmid: 7521238